This guidance from EGPAF is intended for national program managers; technical and clinical advisors; procurement entities; funding agencies; implementing partners; and civil society organizations involved in advocacy, quantification, procurement, distribution, and scale-up of optimal pediatric ARVs. It aims to ensure that these stakeholders are well informed to advocate for and support sustainable access to the full portfolio of optimal pediatric ARVs needed to implement the WHO HIV treatment guidelines. It includes specific guidance on the what, why, who, when, and how of quantifying and supplying the full range of pediatric ARVs.
Comments